[go: up one dir, main page]

MXPA05003253A - Nuevos derivados de pirimidinamida y el uso de los mismos. - Google Patents

Nuevos derivados de pirimidinamida y el uso de los mismos.

Info

Publication number
MXPA05003253A
MXPA05003253A MXPA05003253A MXPA05003253A MXPA05003253A MX PA05003253 A MXPA05003253 A MX PA05003253A MX PA05003253 A MXPA05003253 A MX PA05003253A MX PA05003253 A MXPA05003253 A MX PA05003253A MX PA05003253 A MXPA05003253 A MX PA05003253A
Authority
MX
Mexico
Prior art keywords
derivatives
novel
pyrimidineamide
disease
pyrimidinarnine
Prior art date
Application number
MXPA05003253A
Other languages
English (en)
Inventor
Jacob Sandra
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9944917&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MXPA05003253(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MXPA05003253A publication Critical patent/MXPA05003253A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

La invencion se refiere a nuevos derivados de N-(3-benzoilaminofenil)-4-piridil-2-pirimidinamina sustituidos, procesos para la preparacion de los mismo, composiciones farmaceuticas que contiene los mismos, el uso de los mismos opcionalmente en combinacion con uno o mas compuestos farmaceuticamente activos para la terapia de una enfermedad que responde a una inhibicion de actividad de quinasa de proteina, especialmente una enfermedad neoplastica, y un metodo para el tratamiento de tal enfermedad.
MXPA05003253A 2002-09-27 2003-09-26 Nuevos derivados de pirimidinamida y el uso de los mismos. MXPA05003253A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0222514.2A GB0222514D0 (en) 2002-09-27 2002-09-27 Organic compounds
PCT/EP2003/010724 WO2004029038A1 (en) 2002-09-27 2003-09-26 Novel pyrimidineamide derivatives and the use thereof

Publications (1)

Publication Number Publication Date
MXPA05003253A true MXPA05003253A (es) 2005-06-08

Family

ID=9944917

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05003253A MXPA05003253A (es) 2002-09-27 2003-09-26 Nuevos derivados de pirimidinamida y el uso de los mismos.

Country Status (24)

Country Link
US (1) US7655669B2 (es)
EP (1) EP1546127B1 (es)
JP (2) JP4463685B2 (es)
KR (2) KR20070098940A (es)
CN (1) CN100404528C (es)
AT (1) ATE369355T1 (es)
AU (1) AU2003270277B2 (es)
BR (1) BR0314797A (es)
CA (1) CA2499822C (es)
DE (1) DE60315479T2 (es)
DK (1) DK1546127T3 (es)
EC (1) ECSP055701A (es)
ES (1) ES2288615T3 (es)
GB (1) GB0222514D0 (es)
HK (1) HK1080459A1 (es)
MX (1) MXPA05003253A (es)
NO (1) NO20051966L (es)
NZ (1) NZ538930A (es)
PL (1) PL374443A1 (es)
PT (1) PT1546127E (es)
RU (1) RU2378267C2 (es)
SI (1) SI1546127T1 (es)
WO (1) WO2004029038A1 (es)
ZA (1) ZA200502304B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0222514D0 (en) * 2002-09-27 2002-11-06 Novartis Ag Organic compounds
US7232825B2 (en) * 2003-05-02 2007-06-19 Guoqing P Chen Phenylaminopyrimidine derivatives and methods of use
GB0325031D0 (en) 2003-10-27 2003-12-03 Novartis Ag Organic compounds
DE10352979A1 (de) * 2003-11-13 2005-06-09 Merck Patent Gmbh Pyridopyrimidinone
TW200616974A (en) * 2004-07-01 2006-06-01 Astrazeneca Ab Chemical compounds
AU2005278959A1 (en) 2004-08-31 2006-03-09 Astrazeneca Ab Quinazolinone derivatives and their use as B-Raf inhibitors
PT1786799E (pt) 2004-09-09 2012-09-18 Natco Pharma Ltd Novos derivados de fenilaminopirimidina como inibidores de bcr-abl cinase
US8735415B2 (en) 2004-09-09 2014-05-27 Natco Pharma Limited Acid addition salts of (3,5-Bis trifluoromethyl)-N-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2ylamino)-phenyl]-benzamide
US7939541B2 (en) 2004-09-09 2011-05-10 Natco Pharma Limited Intermediates and a process employing the intermediates for the preparation of (3-trifluoromethylsulfonyl)-N-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2ylamino)-phenyl]-benzamide
CN1939910A (zh) 2004-12-31 2007-04-04 孙飘扬 氨基嘧啶类化合物及其盐和其制备方法与药物用途
US20080114001A1 (en) * 2005-01-28 2008-05-15 Manley Paul W Use of Pyrimidylaminobenzamides for the Treatment of Diseases that Respond to Modulation of Tie-2 Kinase Activity
MY146795A (en) 2005-06-09 2012-09-28 Novartis Ag Process for the synthesis of organic compounds
US20100216791A1 (en) * 2006-08-17 2010-08-26 Astrazeneca Pyridinylquinazolinamine derivatives and their use as b-raf inhibitors
CA2662977A1 (en) 2006-09-22 2008-03-27 Novartis Ag Method of optimizing the treatment of philadelphia-positive leukemia with abl tyrosine kinase inhibitors
KR20120049397A (ko) * 2006-11-03 2012-05-16 노파르티스 아게 단백질 키나제 억제제로서의 화합물 및 조성물
US7550591B2 (en) * 2007-05-02 2009-06-23 Chemagis Ltd. Imatinib production process
CA2686378C (en) * 2007-05-04 2012-07-24 Irm Llc Pyrimidine derivatives and compositions as c-kit and pdgfr kinase inhibitors
BRPI0811516A2 (pt) 2007-05-04 2014-11-18 Irm Llc Compostos e composições como inibidores de c-kit e pdgfr cinase
TWI433677B (zh) 2007-06-04 2014-04-11 Avila Therapeutics Inc 雜環化合物及其用途
ES2477878T3 (es) 2007-08-22 2014-07-18 Irm Llc Compuestos y composiciones de 5-(4-(aloalcoxi)fenil)pirimidin-2-amina como inhibidores de quinasas
ATE520682T1 (de) 2007-08-22 2011-09-15 Irm Llc 2-heteroarylaminopyrimidinderivate als kinaseinhibitoren
US8067422B2 (en) 2008-03-04 2011-11-29 Natco Pharma Limited Crystal form of phenylamino pyrimidine derivatives
AU2011263436A1 (en) * 2010-05-11 2012-08-23 Mahesh Kandula 4, 6 -dibenzoylamino- 2 -methyl- pyrimidine derivatives and their use for the treatment of cancer
JP6106685B2 (ja) 2011-11-17 2017-04-05 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド Ｃ−ｊｕｎ−ｎ−末端キナーゼ（ｊｎｋ）の阻害剤

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0233461B2 (en) 1986-01-13 2002-05-29 American Cyanamid Company 4,5,6-Substituted-2-pyrimidinamines
US5215989A (en) * 1989-12-08 1993-06-01 Merck & Co., Inc. Nitrogen-containing heterocyclic compounds as class III antiarrhythmic agents
TW225528B (es) * 1992-04-03 1994-06-21 Ciba Geigy Ag
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
US5516775A (en) 1992-08-31 1996-05-14 Ciba-Geigy Corporation Further use of pyrimidine derivatives
US5543520A (en) 1993-10-01 1996-08-06 Ciba-Geigy Corporation Pyrimidine derivatives
AU693475B2 (en) 1993-10-01 1998-07-02 Novartis Ag Pyrimidineamine derivatives and processes for the preparation thereof
ITMI992711A1 (it) 1999-12-27 2001-06-27 Novartis Ag Composti organici
US7087608B2 (en) 2000-03-03 2006-08-08 Robert Charles Atkins Use of PDGF receptor tyrosine kinase inhibitors for the treatment of diabetic nephropathy
GB0022438D0 (en) 2000-09-13 2000-11-01 Novartis Ag Organic Compounds
GB0025820D0 (en) 2000-10-20 2000-12-06 Novartis Ag Organic compounds
ATE331519T1 (de) * 2001-05-16 2006-07-15 Gpc Biotech Ag Pyridylpyrimidin-derivate als wirksame verbindungen gegen prionen-krankheiten
GB0222514D0 (en) * 2002-09-27 2002-11-06 Novartis Ag Organic compounds
DE602004028511D1 (de) 2003-12-23 2010-09-16 Koninkl Philips Electronics Nv Bestrahlungsverfahren

Also Published As

Publication number Publication date
ZA200502304B (en) 2006-04-26
ATE369355T1 (de) 2007-08-15
ECSP055701A (es) 2005-05-30
ES2288615T3 (es) 2008-01-16
SI1546127T1 (sl) 2008-08-31
DK1546127T3 (da) 2007-12-10
JP2010043113A (ja) 2010-02-25
CN1684951A (zh) 2005-10-19
AU2003270277A1 (en) 2004-04-19
EP1546127A1 (en) 2005-06-29
US7655669B2 (en) 2010-02-02
PT1546127E (pt) 2007-11-07
DE60315479D1 (de) 2007-09-20
US20060142577A1 (en) 2006-06-29
CA2499822A1 (en) 2004-04-08
RU2005113153A (ru) 2006-11-10
DE60315479T2 (de) 2008-04-30
NO20051966L (no) 2005-04-22
GB0222514D0 (en) 2002-11-06
EP1546127B1 (en) 2007-08-08
JP5178681B2 (ja) 2013-04-10
KR20070098940A (ko) 2007-10-05
PL374443A1 (en) 2005-10-17
KR100876055B1 (ko) 2008-12-26
HK1080459A1 (en) 2006-04-28
AU2003270277B2 (en) 2007-08-23
CN100404528C (zh) 2008-07-23
RU2378267C2 (ru) 2010-01-10
BR0314797A (pt) 2005-07-26
NZ538930A (en) 2008-04-30
JP2006508064A (ja) 2006-03-09
CA2499822C (en) 2012-04-10
JP4463685B2 (ja) 2010-05-19
WO2004029038A1 (en) 2004-04-08
KR20050047128A (ko) 2005-05-19

Similar Documents

Publication Publication Date Title
HK1080459A1 (en) Novel pyrimidineamide derivatives and the use thereof
WO2004005281A8 (en) Inhibitors of tyrosine kinases
TW200615266A (en) Organic compounds
MXPA06000302A (es) Derivados de pirazolil-indol activos como inhibidores de cinasa, procedimientos para su preparacion y composiciones farmaceuticas que los comprenden.
MY142019A (en) Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
MXPA02012272A (es) Compuestos heterociclicos que son inhibidores de la enzima dipeptidilpeptidasa-iv.
WO2004006858A3 (en) Compounds, compositions, and methods employing same
DE602004017194D1 (de) Pyridylpyrrol-derivate als wirksame kinase-hemmer
TW200510375A (en) New compounds
WO2005014572A8 (en) Pyrimidylpyrrole derivatives active as kinase inhibitors
HK1086548A1 (en) Deuterated catecholamine derivatives and medicaments comprising said compounds
IL163951A (en) Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them
GR20020100478A (el) Ανυδρη κρυσταλλικη μορφη της βαλακyκλοβιρης υδροχλωρικης
MXPA04005809A (es) Inhibidores de proteinas quinasas.
MY128529A (en) Use of cilobradine or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure
MXPA05014143A (es) Derivados de cumarina para el tratamiento de trastornos oftalmicos.
TW200502236A (en) Novel pyrido[2,3-d]pyrimidin-7-carboxylic acid derivatives, their manufacture and use as pharmaceutical agents
TW200505913A (en) Novel oxazole derivatives, their manufacture and use as pharmaceutical agents
ZA200209714B (en) Heterocyclic compounds, which are inhibitors of the enzyme DPP-IV.
MXPA05011671A (es) Nuevos derivados de anilina, su manufactura y su uso como agentes farmaceuticos.
AU2003294834A1 (en) Anthranilic acid amide derivatives and their pharmaceutical use
TW200633701A (en) Thioether derivatives, their manufacture and use as pharmaceutical agents
TW200626591A (en) Amide derivatives, their manufacture and use as pharmaceutical agents

Legal Events

Date Code Title Description
FG Grant or registration